Clinical trials have been carried out on antibodies targeting CXCL10 or CD14 in other inflammatory diseases, including rheumatoid arthritis (68), amyotrophic lateral sclerosis (69), and COVID-19 (70). This evidence concerns the gene CXCL10 and rheumatoid arthritis.